Literature DB >> 15542005

Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence.

Mohammad Taghi Joghataie1, Mehrdad Roghani, Fereidoun Negahdar, Leila Hashemi.   

Abstract

Epidemiological studies have consistently demonstrated an inverse association between coffee consumption and Parkinson's disease (PD). This study was designed to investigate the beneficial effect of caffeine at a dose comparable to that of human exposure in a model of PD. For this purpose, unilateral intrastriatal 6-hydroxydopamine (6-OHDA)-lesioned rats were pretreated with caffeine (20 mg/kg; i.p.) 1 h before surgery and treated twice a day (10 mg/kg) for 1 month. Apomorphine-induced rotations and number of Nissl-stained neurons of substantia nigra pars compacta (SNC) were counted. The results demonstrated that caffeine administration for 1 month could attenuate the rotational behavior in lesioned rats and protect the neurons of SNC against 6-OHDA toxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542005     DOI: 10.1016/j.parkreldis.2004.06.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  13 in total

1.  Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

Authors:  Patricia K Sonsalla; Lai-Yoong Wong; Suzan L Harris; Jason R Richardson; Ida Khobahy; Wenhao Li; Bharathi S Gadad; Dwight C German
Journal:  Exp Neurol       Date:  2012-01-28       Impact factor: 5.330

Review 2.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

3.  Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.

Authors:  Anil Kachroo; Michael C Irizarry; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2010-02-24       Impact factor: 5.330

4.  Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.

Authors:  K Xu; D G Di Luca; M Orrú; Y Xu; J-F Chen; M A Schwarzschild
Journal:  Neuroscience       Date:  2016-02-22       Impact factor: 3.590

Review 5.  Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.

Authors:  Robert A Hauser; Michael A Schwarzschild
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 6.  Pathophysiological roles for purines: adenosine, caffeine and urate.

Authors:  Micaela Morelli; Anna R Carta; Anil Kachroo; Michael A Schwarzschild
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 7.  Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.

Authors:  Jacobus P Petzer; Neal Castagnoli; Michael A Schwarzschild; Jiang-Fan Chen; Cornelis J Van der Schyf
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

8.  Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.

Authors:  K Xu; Y-H Xu; J-F Chen; M A Schwarzschild
Journal:  Neuroscience       Date:  2010-02-16       Impact factor: 3.590

9.  The promise of neuroprotective agents in Parkinson's disease.

Authors:  Stacey E Seidl; Judith A Potashkin
Journal:  Front Neurol       Date:  2011-11-21       Impact factor: 4.003

Review 10.  Caffeine: cognitive and physical performance enhancer or psychoactive drug?

Authors:  Simone Cappelletti; Daria Piacentino; Piacentino Daria; Gabriele Sani; Mariarosaria Aromatario
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.